UK Drugs Inquiry: Drug Science Response

In 2019, Drug Science submitted evidence to the Drugs Policy Inquiry by the Health and Social Care Committee. In 2020, we prepared a detailed report in response to the Dame Carol Black Drugs Review. In 2021, we reacted to the government’s 10-year Drug Strategy. Our 2022 response to the UK government’s call for evidence of  …


Parliamentary briefing on tackling the misuse of Nitrous Oxide

This Parliamentary briefing has been prepared by DrugScience, The Global Drug Survey, Release and Transform Drug Policy Foundation.   Recreational use of nitrous oxide Nitrous oxide is a gas that was discovered in the late 1800s by UK scientists Priestley and Davy, the latter being President of the Royal Society. At the time nitrous oxide  …


The Unintended Consequences of Prohibitionist Policies - Mephedrone

Mephedrone is the common name for 4-methylmethcathinone. This is a synthetic derivative of cathinone, first synthesized in 1929, and largely forgotten until the early 2000s when Israeli scientists working for an insecticide company started experimenting with cathinones as octopamine analogues to disrupt the brain activity of aphids so make them less damaging to plants. Mephedrone  …


UK General Election 2019 - Political party positions on drugs

With the 2019 general election fast approaching, a lot of media coverage will focus on each party’s Brexit policies. Drug Science would like to offer a different perspective, what do the six highest polling parties promise to do to address the UK’s failing drug policy. This is what each party has publicly announced relating to  …


Response to the Nature article: Moving from prison to PhD

There are fewer than ten empirical studies on the transition from prison to university so the article “Moving from Prison to PhD” is a step in the right direction to highlight this neglected and important topic. Globally, millions of individuals are arrested and charged with drug offences every year. Most of them will be scarred  …


Statement on the dangers posed by e-cigarettes

Drug Science stands by its e-cigarette analysis from 2014, any way of radically reducing the death toll from tobacco would be a worldwide public health triumph. e-cigarettes are not the solution to end the ever-increasing death toll caused by tobacco. However, they have proven to be an incredibly effective tool for tens of thousands of  …


New Zealand revises sentencing framework for methamphetamine offences

Dr James Foulds, Consultant forensic psychiatrist, Christchurch New Zealand Methamphetamine smoking is the commonest form of stimulant use in New Zealand. Asian importation has increased recently, and the drug has got much cheaper. However, despite harsh sanctions, dealing remains attractive for many people- including those who sell the drug to fund their own use. Until  …


Drug Science gives evidence to the Health and Social Care Committee on Medicinal Cannabis

On 1 November 2018, following considerable popular pressure surrounding a select number of young children with treatment-resistant epilepsy who responded well to medicinal cannabis (and medicinal cannabis alone), regulations in the UK came into force to reschedule cannabis‑derived medicinal products to schedule 2 of the Misuse of Drugs Regulations 2001 and to allow prescribing of  …

DrugScience Symposium 'Cannabis medicines: from principle to practice. How can we maximise clinical research and benefits?'

Please download the conference background materials here, including: Meeting slides DrugScience report on medicinal cannabis DrugScience cannabis pre-review submitted to the WHO Expert Committee on Drug Dependence Summaries of international and American medicinal cannabis licensing The Chief Medical Officer and advisor to the UK government has recently agreed that cannabis is a medicine. It has  …


ACMD advice on cannabis-derived medicinal products

On 11 September 2018, the ACMD published its Advice to the Home Secretary and to the Secretary of State for Health and Social Care. It is a constructive document that highlights a number of issues and problems that this commentator has raised for some time. In some respects the document is nuanced. Doubtless in the  …

Harm Reduction in Public Policy - the UK and the US – A DrugScience evening reception at the House of Lords

On Wednesday 30 May 2018, DrugScience hosted an evening reception at the House of Lords, in partnership with Harm Reduction International. Sponsored by DrugScience trustee Lord Nick Rea, the evening featured presentations on the latest strategic approaches to reduce the negative consequences associated with risk behaviours and addiction, the challenging global funding environment for harm  …

Letter to The Times: Legalise medicinal cannabis

A letter to The Times from coalition of world-leading clinicians and academics, many of whom are DrugScience members, urging the government to legalise medical cannabis. Related Content UK Drugs Inquiry: Drug Science ResponseApril 25 2022 Legalising Cannabis in Germany - High AmbitionsNovember 29 2021 “We're asking for quality of life for our children” - Medical  …

Ketamine as an essential medicine

Authors: Polly Taylor, David Nutt, Val Curran, Rudi Fortson, and Graeme Henderson Published: March 11, 2016 A letter to The Lancet endorsing the WHO Expert Committee on Drug Dependence's conclusion that concerns over recreational ketamine abuse in no way outweigh ketamine's role as a life-saving anasthetic and essential medicine. For open-access to the full report  …

Briefing notes on the Psychoactive Substances Bill 2015

The DrugScience group met on Thursday 1 June, and the major item for discussion was the new Psychoactive Substances Bill. The Bill will have its second reading in the House of Commons on 9th June 2015. The following points were made and are presented here for public information and dissemination. 1 Issues of principle 1.1  …

Amphetamine driving consultation 2015

Below is DrugScience's response to the Government's consultation on new regulations on driving with amphetamine in the body. Do you agree with the Government’s proposed limit for amphetamine? If not please provide your reason(s). No, DrugScience does not agree with the proposed limit of 50µg/L. As stated in our response to the last consultation, DrugScience  …

New Psychoactive Substances - a minimum dataset

The collection of scientific evidence about novel psychoactive substances is essential for guiding appropriate responses and reducing harm. DrugScience has prepared the following list of fundamental pieces of information, a 'minimum dataset' that should be sought for each novel drug. We recommend that for political responses to concerns about novel drugs to be 'evidence-based', it  …

Harms of nicotine-containing products

Around the world, politicians are working to ban e-cigarette marketing, limit their nicotine content, prohibit use in public buildings, and even to ban them entirely. There remains a need for policy makers to become better informed of the relative harms of nicotine delivery systems in order to build a regulatory framework that minimises harm. The  …


Drug driving consultation 2013

Below is DrugScience’s response to the Government’s drug driving consultation. The consultation has now closed. Parliament will not be debating these changes in full as despite their serious nature, they are to be instituted through an amendment of the Road Traffic Act 1988 (secondary legislation). Do you agree with the Government’s proposed approach as set  …


MCDA Comparison of Drug and Alcohol Harms in the UK

Authors: David J Nutt, Leslie A King, and Lawrence D Phillips Published: November 1, 2010 An assessment of the various harms of drugs used recreationally in the UK using multi-criteria decision analysis (MCDA) – a method that uses relevant experts’ knowledge and experience to assess the actual and relative harms - download the paper here.  …